Biomerica Announces Fiscal Year End 2018 Financial Results
August 30, 2018 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2018 were $5,564,185...
Cognoa Demonstrates Advances of its AI-Based Technology for Identifying Autism in Children
August 27, 2018 13:49 ET
|
Cognoa
PALO ALTO, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Cognoa, a digital behavioral health company, today announces results from a clinical study of its second-generation AI based algorithms which...
InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS
May 30, 2018 07:31 ET
|
InspireMD, Inc.
Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE...
VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
May 10, 2018 07:30 ET
|
VBI Vaccines, Inc.
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest doseSafe and well-tolerated at all doses with no safety signals observedConference...
VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update
May 01, 2018 08:00 ET
|
VBI Vaccines, Inc.
-- Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac® Hepatitis B Vaccine -- -- Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of...
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
April 17, 2018 08:00 ET
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationLow-dose study arm: enrollment completeIntermediate-dose study arm: enrollment...
InspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard EPS Compared to Another Next Generation Carotid Stent
January 19, 2018 10:18 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 19, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
Vitality Biopharma Introduces Cannabinoid Pharmaceutical VITA-100 as Prodrug of THC
January 03, 2018 08:30 ET
|
Vitality Biopharma, Inc
LOS ANGELES, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...
VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
December 19, 2017 08:00 ET
|
VBI Vaccines, Inc.
Patient dosing commenced on December 18, 20174,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE...
Mucodel Pharma LLC Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation
December 11, 2017 07:30 ET
|
Mucodel Pharma LLC
Greensboro, NC, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving intranasal naloxone, a Mucodel...